

**Appendix 2** Detailed study characteristics of included IPPIC cohorts

| Study/Dataset          | Study design  | Data source          | Country   | Data period | Population type (any pregnancy, high risk[women with complications], low risk) | Inclusion criteria  | Exclusion criteria  |
|------------------------|---------------|----------------------|-----------|-------------|--|---|---|
| Allen RE 2017          | Observational | Prospective cohort   | UK        | 2010-2014   | Any pregnancy  | All pregnant women attending an inner London hospital between 11-14 weeks gestation                         | Women with multiple pregnancies and fetal anomalies   |
| Rumbold AR 2006        | Randomised    | Trial                | Australia | 2001-2005   | Low risk   | Nulliparous women with a singleton pregnancy between 14 and 22 weeks of gestation and normal blood pressure | Known multiple pregnancy, known potentially lethal fetal anomaly, known thrombophilia, chronic renal failure, antihypertensive therapy, or specific contraindications to vitamin C or E therapy such as hemochromatosis or anticoagulant therapy. |
| Stork-Groruddalen 2010 | Observational | Prospective cohort   | Norway    | 2008-2010   | Any pregnancy  | Healthy pregnant women  | Women with diabetes or diseases requiring intensive hospital follow-up in pregnancy   |
| NICHD 2018             | Observational | Retrospective cohort | USA       | 2002-2008   | Any pregnancy  | All deliveries $\geq 23$ weeks gestation from 19 hospitals across the US                                    | None  |